STOCK TITAN

NEVRO CORP. - NVRO STOCK NEWS

Welcome to our dedicated page for NEVRO news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on NEVRO stock.

Nevro Corp. (NYSE: NVRO), headquartered in Redwood City, California, is a pioneering global medical device company dedicated to improving the lives of patients suffering from chronic pain through innovative products. The company's flagship product, the Senza® Spinal Cord Stimulation (SCS) System, is an evidence-based neuromodulation platform designed to treat chronic pain. This system features Nevro's proprietary HF10 therapy, which is known for its high-frequency, paresthesia-free stimulation, approved by the FDA in 2015, and commercially available in the U.S., Europe, and Australia.

Nevro's comprehensive product portfolio includes the HFX™ Spinal Cord Stimulation (SCS) Platform, comprising Senza®, Senza II®, Senza Omnia®, and HFX iQ™ systems. These devices offer patients a non-pharmacologic solution to manage chronic pain and painful diabetic neuropathy, providing sustainable pain relief and improved quality of life. The HFX platform also includes support services such as HFX Coach™ for patients and HFX Cloud™ for physicians, ensuring enhanced patient management and outcomes.

In November 2023, Nevro expanded its portfolio by acquiring Vyrsa Technologies, a company specializing in minimally invasive sacroiliac joint (SI joint) fusion devices. This strategic move allows Nevro to address a broader range of chronic pain conditions, particularly chronic SI joint pain. Vyrsa's innovative implants and proprietary technologies complement Nevro's existing offerings, positioning the company for significant market penetration and growth.

Financially, Nevro has shown resilience and adaptability. For the full year of 2023, the company reported worldwide revenues of $425.2 million, reflecting a 5% increase from the previous year. Despite challenges, Nevro's solid performance is attributed to its continuous focus on commercial execution, market penetration, and profitability. The company recently secured a $200 million term loan credit facility to refinance its 2025 convertible notes and ensure long-term financial stability.

Nevro's commitment to innovation is further evidenced by the recent FDA clearance of its sacroiliac joint fusion device, Nevro1, which is designed to enhance the stability and fusion of the SI joint using proprietary transfixing technology and bone-growth enhancing materials. This product, alongside the existing portfolio, reinforces Nevro's leadership in the chronic pain management market.

The company also maintains strong strategic partnerships and collaborations, ensuring that its solutions reach a wide patient base. Recent policy updates, such as the expansion of coverage for spinal cord stimulation for painful diabetic neuropathy by Carelon Healthcare, have significantly increased access to Nevro's therapies, benefiting millions of patients across the United States.

Going forward, Nevro remains dedicated to its mission of delivering life-changing solutions for chronic pain, continuously advancing its product offerings, and maintaining its commitment to improving patient outcomes globally.

Rhea-AI Summary

Nevro Corp. has responded to Medtronic's FDA approval for painful diabetic neuropathy (PDN), highlighting the significant market potential for this condition. The company asserts its SENZA-PDN trial is the largest and most comprehensive for spinal cord stimulation therapy, yielding superior outcomes compared to Medtronic's studies. Nevro claims its proprietary 10 kHz Therapy offers advantages in pain relief, treatment success rates, and neurological improvement. The company expresses concern over Medtronic's reliance on older studies for FDA approval, emphasizing the robust data from their SENZA-PDN trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a medical device company, will announce its fourth quarter and full-year 2021 financial results on February 23, 2022. The report will be released after market close, followed by a conference call at 1:30 PM PT to discuss the results. Interested investors can access the call by dialing (888) 330-2443 or +1 (240) 789-2728 internationally, using Conference ID: 3583097. Nevro, based in Redwood City, California, specializes in chronic pain solutions and is known for its 10 kHz Therapy benefiting over 80,000 patients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences earnings
-
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), based in Redwood City, California, has received FDA approval for expanded labeling of its Senza® Spinal Cord Stimulation (SCS) System to treat Non-Surgical Refractory Back Pain (NSRBP), marking it the only SCS system specifically indicated for this condition. This approval highlights Nevro's proprietary 10 kHz Therapy. Clinical trials indicate significant improvements in pain relief and quality of life for patients after 12 months of treatment. Nevro aims to enhance market access and payer coverage based on these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
Rhea-AI Summary

Nevro Corp. announced significant outcomes from its clinical trials presented at the 2022 North American Neuromodulation Society Annual Meeting. The SENZA-PDN trial demonstrated durable efficacy for 10 kHz spinal cord stimulation in painful diabetic neuropathy at 18 months, with no explants due to loss of efficacy. The SENZA-NSRBP trial showed profound pain relief and improved quality of life in patients at 12 months, supported by cost-effectiveness data for the treatment. Nevro aims to be the only SCS company with an on-label indication for treating non-surgical refractory back pain upon FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) reported preliminary unaudited revenue results for Q4 and full-year 2021, expecting Q4 revenue of approximately $102.5 million, down from $109.7 million YoY. Full-year revenue is expected at $386.6 million, up from $362.0 million in 2020. Despite Q4 declines, U.S. trial procedures rose 3%, with painful diabetic neuropathy (PDN) trials growing 92% sequentially. Nevro anticipates exceeding its adjusted EBITDA guidance of negative $10 million to negative $13 million. The company plans to report full financial results on February 23, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
none
-
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) announced that UnitedHealthcare will provide coverage for its high-frequency 10 kHz Therapy for Painful Diabetic Neuropathy (PDN), effective March 1, 2022. This decision is seen as a major milestone in facilitating access to Nevro's FDA-approved spinal cord stimulation therapy. UnitedHealthcare’s policy considers this treatment medically necessary under specific criteria. Nevro believes this coverage will enhance its market position and lead to further endorsements from additional health plans, supported by extensive clinical data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
none
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) announced a settlement of its patent lawsuit against Nalu Medical regarding high-frequency spinal cord stimulation (SCS) technology. Initially filed in February 2020, Nevro accused Nalu of patent infringement, but the lawsuit concluded with both parties agreeing to avoid further litigation costs. Nevro's General Counsel, Kashif Rashid, emphasized the importance of protecting intellectual property. Nevro remains the sole provider of FDA-approved high-frequency SCS therapy for painful diabetic neuropathy, allowing them to focus on developing solutions for chronic pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
conferences
-
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) announced that three abstracts related to Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) have been accepted for podium presentations at the NANS 2022 Annual Meeting on January 15, 2022. The presentations will showcase critical results from the largest randomized controlled trial of spinal cord stimulation for PDN, involving 216 subjects, and 12-month outcomes from a similar trial for NSRBP with 159 participants. A focus will also be on the cost-effectiveness of their 10 kHz spinal cord stimulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a leader in innovative medical devices for chronic pain, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. D. Keith Grossman, Chairman, CEO, and President, will present on January 10, 2022, at 7:30 am PT in San Francisco, CA. A live webcast will be accessible on Nevro's website. The company focuses on the Senza spinal cord stimulation system, which offers evidence-based, non-pharmacologic pain management solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
conferences

FAQ

What is the current stock price of NEVRO (NVRO)?

The current stock price of NEVRO (NVRO) is $3.79 as of December 20, 2024.

What is the market cap of NEVRO (NVRO)?

The market cap of NEVRO (NVRO) is approximately 140.9M.

What is Nevro Corp's core business?

Nevro Corp is a global medical device company focused on delivering innovative products for the treatment of chronic pain, including the Senza spinal cord stimulation (SCS) system and the HFX spinal cord stimulation platform.

What is the Senza SCS system?

The Senza SCS system is an evidence-based neuromodulation platform that delivers Nevro's proprietary HF10 therapy, designed to relieve chronic pain without the paresthesia typical of traditional SCS systems.

What recent acquisition has Nevro Corp made?

In November 2023, Nevro Corp acquired Vyrsa Technologies, a company specializing in minimally invasive sacroiliac joint fusion devices, to expand its chronic pain treatment portfolio.

What financial performance did Nevro Corp report for 2023?

Nevro reported worldwide revenues of $425.2 million for the full year of 2023, a 5% increase from 2022, driven by robust product sales and strategic initiatives.

What are some of Nevro's key products?

Nevro's key products include the Senza®, Senza II®, Senza Omnia®, and HFX iQ™ spinal cord stimulation systems, as well as SI joint fusion devices acquired from Vyrsa Technologies.

What support services does Nevro provide?

Nevro offers HFX Coach™ for patient support and HFX Cloud™ for physician insights, ensuring comprehensive care and improved patient and practice management.

What is HF10 therapy?

HF10 therapy is Nevro's proprietary high-frequency, paresthesia-free spinal cord stimulation technology, designed to provide sustained pain relief without the uncomfortable sensations associated with traditional SCS.

How has Nevro expanded access to its therapies?

Carelon Healthcare's recent policy expansion has increased coverage for Nevro’s spinal cord stimulation therapy for painful diabetic neuropathy, broadening access to millions of patients.

What are Nevro's strategic goals?

Nevro aims to drive long-term shareholder value through commercial execution, market penetration, and profit progress, supported by continuous product innovation and strategic acquisitions.

What new product did Nevro recently receive FDA clearance for?

Nevro recently received FDA clearance for its sacroiliac joint fusion device, Nevro1, which uses innovative transfixing technology and bone-growth enhancing materials for optimal joint stability and fusion.

NEVRO CORP.

NYSE:NVRO

NVRO Rankings

NVRO Stock Data

140.89M
36.06M
3.69%
103.89%
6.98%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY